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Sinorhizobium meliloti, a legume symbiont, and Brucella abortus,
a phylogenetically related mammalian pathogen, both require the
bacterial-encoded BacA protein to establish chronic intracellular
infections in their respective hosts. We found that the bacterial
BacA proteins share sequence similarity with a family of eukaryotic
peroxisomal-membrane proteins, including the human adrenoleu-
kodystrophy protein, required for the efficient transport of very-
long-chain fatty acids out of the cytoplasm. This insight, along with
the increased sensitivity of BacA-deficient mutants to detergents
and cell envelope-disrupting agents, led us to discover that BacA
affects the very-long-chain fatty acid (27-OHC28:0 and 29-OHC30:0)
content of both Sinorhizobium and Brucella lipid A. We discuss
models for how BacA function affects the lipid-A fatty-acid content
and why this activity could be important for the establishment of
chronic intracellular infections.
S inorhizobia and brucellae are Gram-negative -proteobac-teria that live intracellularly within their respective hosts.
Sinorhizobia form a beneficial symbiosis with agriculturally
important legumes that results in the conversion of N2 to NH3
(1). In contrast, brucellae are highly infectious pathogens that
cause abortions and infertility in domestic and wild mammals
and a severe and debilitating zoonotic disease in humans (2).
Brucella melitensis, Brucella suis, and Brucella abortus are po-
tential biological warfare agents, and they are a serious concern
because there is presently no human vaccine (3). Despite the
strikingly different outcomes that sinorhizobia and brucellae
eventually have on their hosts, commonalties exist in the chronic-
infection process because both are endocytosed into host cells,
where they adapt and survive for extensive periods of time within
acidic, membrane-bound compartments (1, 2, 4, 5). More im-
portantly, the close phylogenetic relatedness of the sinorhizobia
and the brucellae that was revealed initially by RNA homology
studies has been confirmed recently by determination of the
complete genome sequences of Sinorhizobium meliloti, B.
melitensis, and B. suis (6–8).
The BacA protein, initially found to be essential for S. meliloti
to form a long-term infection within alfalfa-plant cells (9), was
also shown subsequently to be essential for the establishment and
maintenance of chronic spleen and liver infections by B. abortus
in BALBc mice (10). BacA is predicted to span the inner
membrane of S. meliloti and B. abortus seven times, and it is
homologous to the SbmA protein of Escherichia coli, a putative
transporter of peptide antibiotics (9, 11). Although an S. meliloti
bacA null mutant displays altered sensitivity to peptide antibi-
otics (11), the increased sensitivity of this mutant to detergents
and cell envelope-disrupting agents supports an alternative
model wherein the function of BacA affects the integrity of the
bacterial cell envelope (12). Recently, an S. meliloti lpsB mutant,
altered dramatically in its lipopolysaccharide (LPS) carbohy-
drate content, was found to be defective at the same stage as a
bacA mutant in establishing a chronic infection of alfalfa nodule
cells (13). Unlike the S. meliloti lpsB mutant, however, the S.
meliloti bacA mutant does not have a dramatic alteration in the
carbohydrate composition of its LPS (12). Here, we report our
findings that the S. meliloti and B. abortus BacA proteins,
essential for the chronic-infection process in plants and animals,
respectively, are related distantly to a family of peroxisomal-
membrane proteins. This insight, combined with our physiology
data for S. meliloti and B. abortus bacA null mutants that
suggested that they had altered cell envelopes, led us to discover
that BacA affects the LPS fatty-acid content.
Materials and Methods
Bacterial Growth and LPS Extraction. The sequenced S. meliloti
strain Rm1021 (wild type) and an isogenic Rm1021 bacA null
mutant were used in this study (11, 12). The plasmids pBacA
D198G, pBacA R284G, pBacA Q193G, and pBacA R389G
containing site-directed mutations in the S. meliloti bacA gene
were constructed (14). Expression of the site-directed mutant
BacA proteins was determined by a dominant-negative test in the
presence of the wild-type BacA protein. For this study, the bacA
mutant plasmids were transferred from E. coli into the Rm1021
bacA null mutant by triparental mating by using an E. coli strain
containing the helper plasmid pRK600. As described in the
Rm8002 bacA null background (14), all four mutant BacA
proteins produced from the plasmids in the Rm1021 bacA null
background were unable to function in the alfalfa symbiosis
(data not shown). As controls, the plasmid pRK404 alone with
no insert (pControl) and the plasmid pJG51A (9) containing a
wild-type S. meliloti bacA gene (pBacAWT) were also trans-
ferred to Rm1021 bacA null mutant, and they produced the
expected responses on alfalfa plants (11).
For the LPS extractions, cultures of the appropriate S. meliloti
strain were grown to stationary phase in Luria–Bertani (LB)
media supplemented with 2.5 mM MgS042.5 mM CaCl2500
gml1 streptomycin (Sm500). The cultures were then centri-
fuged, and cell pellets were washed with LB, resuspended to
OD600 0.2 in 4 liters of LBSm500 and grown until midexpo-
nential phase (OD600 1–2). The bacteria were then harvested
by centrifugation and resuspended in 150 ml of EDTA solution
(0.05 M Na2HPO45 mM EDTA), and the LPS was extracted
into the aqueous phase by using a hot phenolwater extraction
procedure (15). LPS was extracted from LB-grown cultures
because it has been shown (12) that divalent cations increase the
stress resistance of S. meliloti and mask the phenotypes of an S.
meliloti bacA null mutant. When S. meliloti-containing plasmids
were grown, the media was also supplemented with 5 gml1
tetracycline.
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B. abortus is a biosafety level 3 pathogen that is highly
infectious by means of the aerosol route in a laboratory setting.
To avoid potential aerosol exposure associated with the pro-
cessing of large-scale liquid cultures, B. abortus strains were
cultivated on solid growth medium. B. abortus 2308 and the bacA
null mutant KL7 (10) were streaked from 80°C stocks onto
Schaedler agar (Becton Dickinson) supplemented with 5%
defibrinated bovine blood and incubated at 37°C for 48–72 h.
The colonies from five plates were pooled, and the brucellae
were heat-killed after a standard procedure (16). After testing
for loss of viability, the LPS was extracted under BL2 conditions
from at least four combined pools by using the hot phenolwater
procedure (15). The LPS from B. abortus partitions into the
phenol phase, as described (17). Deoxycholate gradient plates
were prepared as described, except that Brucella broth agar
(Becton Dickinson) replaced LB agar (12).
Lipid-A Isolation. Lipid A was isolated from the crude LPS
extractions by mild-acid hydrolysis (18). LPS (5 mg) was
dissolved in 1 ml of 1% SDS in 10 mM sodium acetate (pH
adjusted to 4.5 with 4 M HCl) and dissolved by incubation in an
ultrasound bath. The sample was then heated 100°C for 1 h and
freeze-dried, and the SDS was removed by washing the dried
residue with 100 l of distilled water and 500 l of acidified
ethanol (prepared by combining 100 l of 4 M HCl with 20 ml
of 95% ethanol), followed by centrifugation (2,000  g, 20 min).
The sample was then washed with 500 l of nonacidified 95%
ethanol and centrifuged. The centrifugation steps and washing
steps were then repeated. Finally, the sample was lyophilized to
give purified lipid A.
Matrix-Assisted Laser Desorption Ionization–Time of Flight (MALDI–
TOF) MS of Purified Lipid A. Lipid A samples were analyzed by
MALDI–TOF MS by using an LD–TOF system (Hewlett–
Packard). Lipid A samples were prepared to a concentration of
2 gml1 in 2:1 CHCl3CH3OH, and 1 l was mixed with the
matrix (trihydroxyacetone in methanol) for analysis. These con-
ditions were essential to solubilize lipid A with and without
very-long-chain fatty acid (VLCFA) modifications. The pro-
posed composition of the major identified lipid A species were
determined based on the GC–MS fatty-acid composition data
and the reported structures of the Sinorhizobium NGR234 (19)
and B. abortus (20) lipid A species.
Lipid A Fatty-Acid Quantification by GC–MS. The fatty acids were
identified and quantitated by combined GC–MS of their tri-
methylsilyl (TMS) ether (because these are hydroxy fatty acids)
methyl esters. Each sample was treated with methanolic 1 M HCl
at 80°C for 18 h. The methanolic HCl was then evaporated by
using a stream of nitrogen, and the TMS derivatives were
prepared by the addition of TriSil reagent (Pierce) and heating
at 80°C for 25 min. The solvent was removed by using a stream
of nitrogen, and the resulting TMS fatty-acid methyl esters were
dissolved in hexane and analyzed by GC–MS using a 30-m DB-5
capillary column (J & W Scientific, Folsom, CA).
Results
BacA Shares Sequence Similarity with Peroxisomal-Membrane Pro-
teins. A possible function for BacA was suggested by our obser-
vation that its sequence shares similarity with a family of
peroxisomal-membrane proteins that include the human adre-
noleukodystrophy protein (hALDP) (Fig. 1A), consistent with
the idea that BacA is a distant member of this family. This finding
was intriguing because several members of this family are
thought to be involved in the efficient transport of either
VLCFAs or long-chain fatty acids out of the cytoplasm into
peroxisome, where they can then be degraded (21–24). One
member of this family, hALDP, is affected in patients with
X-linked adrenoleukodystrophy (25), an X-linked disorder that
is secondary to a mutation in the ABCD1 gene (which encodes
hALDP). Genetic defects in hALDP result in defects in perox-
isomal -oxidation (21) and the accumulation of VLCFAs in all
tissues of the body (26). Our analysis has revealed that several
identified (25) missense mutations that alter hALDP function
affect amino acids conserved with S. meliloti BacA (Fig. 1 A). We
also determined by using information from a genetic study (14)
of S. meliloti bacA missense mutants that changes in four
different amino acids in BacA, which prevent BacA from func-
tioning effectively in the symbiosis with alfalfa plants, are
conserved with amino acids in hALDP (Fig. 1 A).
Sinorhizobium and Brucella BacA Affect Lipid A Fatty Acids. The
involvement of hALDP in a process involving VLCFAs was of
particular interest because Sinorhizobium and Brucella LPS each
contain a saturated VLCFA of 27-OHC28:0, 27-O (OMeC4:0)
C28:0, or 29-OHC30:0 (27). VLCFAs are attached to the lipid-A
component of Sinorhizobium LPS (Fig. 1B), and each lipid-A
molecule of free-living wild-type sinorhizobia contains one
VLCFA (Fig. 2A and Table 1); lipid A lacking VLCFAs was not
detected in wild-type S. meliloti. Given the relationship between
BacA and hALDP, it seemed to be possible that BacA might
affect the VLCFA content of S. meliloti LPS. We found that
more than one half of the lipid-A molecules isolated from the S.
meliloti bacA null mutant, in contrast to lipid A from wild-type
sinorhizobia, lacked either a 27-OHC28:0 or 27-O (OMeC4:0)
C28:0 modification (Fig. 2B and Table 1). Furthermore, com-
positional analysis of the lipid-A fatty acids revealed that the S.
meliloti bacA null mutant had a significant decrease in both the
27-OHC28:0 and 29-OHC30:0 levels compared with wild-type S.
meliloti, whereas the levels of 3-OHC20:1 or shorter were not
reduced (Fig. 2C). The remaining VLCFA modification of the
lipid A that occurred in the bacA null mutant was not due to
residual BacA activity because the entire promoter and70% of
the bacA coding sequence had been replaced with a spectino-
mycin cassette during the creation of the S. meliloti bacA null
mutant (11).
Because the B. abortus bacA null mutant is defective also at
long-term survival within the host cell (10), we rationalized that
it could have an alteration resembling that of the S. meliloti bacA
null mutant in its LPS. Similar to S. meliloti, we found that each
molecule of lipid A from wild-type B. abortus contains a VLCFA
modification (Fig. 2D and Table 1), whereas a significant fraction
of the lipid A extracted from the B. abortus bacA null mutant
lacked either a 27-OHC28:0 or 27-O (OMeC4:0) C28:0 mod-
ification (Fig. 2E and Table 1). However, unlike the S. meliloti
bacA null mutant lipid A, the brucellae lipid-A molecules lacking
VLCFAs also lacked either a 3-OHC14:0 or 3-OHC12:0 modi-
fication (Fig. 2E and Table 1). The lipid-A fatty-acid composi-
tion data showed that the B. abortus bacA null mutant had the
greatest reduction in 27-OHC28:0 and 29-OHC30:0 levels com-
pared with wild-type B. abortus, with a lesser reduction in some
of the shorter-chain fatty acids (Fig. 2F). Consistent with an
alteration in the cell envelope, we observed that the B. abortus
bacA mutant also displayed an increased sensitivity to detergents
(data not shown), as has been described for the S. meliloti bacA
null mutant (12).
Changes in BacA Residues Conserved with hALDP Affect Lipid-A Fatty
Acids. As described, we discovered that changes in four different
amino acids in the S. meliloti BacA protein that are conserved
with amino acids in hALDP (Fig. 1 A) prevent S. meliloti from
establishing a chronic infection in alfalfa-plant cells. For three of
these mutants, changes in the corresponding conserved residue
in hALDP have been detected in X-linked adrenoleukodystro-
phy patients (Fig. 1 A). Analysis of the lipid A from these four
S. meliloti bacA missense mutants revealed that, unlike the









wild-type strain, they all produced a lipid-A species lacking a
VLCFA (Fig. 3 and Table 1). However, the proportion of the
different lipid-A species present in each mutant varied. Intrigu-
ingly, the S. meliloti bacA missense mutant R389G (14) produced
only a relatively small fraction (20%) of its total lipid-A
molecules lacking VLCFAs compared with the bacA null mutant
(Fig. 3 C and D), yet it was completely defective in forming a
chronic infection in alfalfa. As with the S. meliloti bacA null
mutant, the bacA missense mutants did not affect the shorter-
chain lipid-A fatty acids (data not shown).
Discussion
Our data show that both S. meliloti and B. abortus BacA proteins
have striking effects on the modification of at least one cell-
envelope component, the LPS, by specific fatty acids. This is
clear evidence that BacA, an integral membrane protein origi-
nally postulated to be a peptide transporter (9), affects specific
fatty acids rather than peptides. The fact that BacA affects the
degree of modification of the LPS by VLCFAs (27-OHC28:0 and
29-OHC30:0), taken together with the sequence similarity of BacA
to the adrenoleukodystrophy family of proteins [some of which
affect transport of activated long (C18) and VLCFAs (C22) (21,
22–24)], suggests that the molecular mechanism of BacA action is
related to that of human ALDP and other peroxisomal-membrane
proteins. As described above, BacA function is critically required
for S. meliloti symbiosis and B. abortus chronic pathogenesis (9, 10).
Thus, the fact that BacA affects the VLCFA modification of a
cell-envelope component, the LPS, both in S. meliloti and B. abortus,
is consistent with the hypothesis that a BacA-mediated change in
the VLCFA modification of the LPS andor some other cell-
envelope component is critically important for the chronic intra-
cellular infections that underlie S. meliloti symbiosis and B. abortus
chronic pathogenesis.
There are outstanding questions to be resolved from our
analyses. (i) Is the lipid-A modification in the bacA mutants the
Fig. 1. Alignment of BacA proteins with proteins affecting long-chain fatty acid and VLCFA transport and structure of major lipid A in S. meliloti showing VLCFA
modification. By using position-specific iterative BLAST (NCBI), we identified that S. meliloti BacA appears to be distantly related to the central domain of a family
of peroxisomal-membrane proteins (position-specific iterative BLAST results showed that S. meliloti BacA residues 63–418 share 32% similarity and 12% identity
with residues 98–453 of the Neurospora crassa related to adrenoleukodystrophy protein). Standard BLAST (NCBI), as had been used in our earlier sequence
comparisons of S. meliloti BacA (14), does not detect this similarity. (A) Clustal T-Coffee 1.41 (available at http:ch.EMBnet.org) (see ref. 45) was then used to
align bacterial BacA proteins with several members of the peroxisomal-membrane protein family. The following protein sequences were aligned: S. meliloti BacA
(SmBacA; GenBank accession no. CAC49525), B. abortus BacA (BaBacA; GenBank accession no. AAF76873), N. crassa related to hALDP (NcrALDP; GenBank
accession no. CAB91246), hALDP (GenBank accession no. P33897), human 70-kDa peroxisomal-membrane protein (h70Kda; GenBank accession no. CAA4146),
and Arabidopsis thaliana PXA1 (AtPXA1, also known as COMATOSE, NP568072), both N- and C-terminal domains. Identical and similar residues throughout the
alignment are shown in black and gray, respectively, by using the parameters of BOX SHADE 3.21 (available at http:ch.EMBnet.org). Human ALDP residues altered
in X-linked adrenoleukodystrophy patients that affect residues conserved with S. meliloti BacA residues are indicated (*); the precise hALDP residues changes
are shown. Arrows indicate the four residues altered in the S. meliloti bacA missense mutants (pBacA Q193G, pBacA D198G, pBacA R284G, and R389G) (14) that
change residues conserved with hALDP. (B) Major lipid-A species in free-living S. meliloti, as determined by our composition analysis (see Fig. 2) and the mass
spectra of the published lipid-A species of Sinorhizobium NGR234 (19). The lipid-A molecule shown is modified by 27-OHC28:0, which can be replaced by 27-O
(OMeC4:0) C28:0 (forming another major species) or 29-OHC30:0 (forming a minor species).
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proximal cause of the symbioticchronic pathogenesis defects
and, if so, what is the mechanism for this? (ii) What is the
molecular mechanism of the BacA protein? And (iii) why do the
bacA mutants still produce some lipid A with a VLCFA modi-
fication? We will now address each of these questions in turn. For
acute intracellular pathogens such as Salmonella enterica serovar
Typhimurium, changes in the lipid-A structure are known to
have a profound effect on virulence and resistance against
vertebrate antimicrobial peptides (28–30). In contrast, the role
of lipid A in the establishment of chronic intracellular infections
is poorly understood. Thus, an attractive model is that the
observed alterations in the fatty-acid modification of the lipid A
in S. meliloti and B. abortus bacA mutants are responsible, at least
in part, for their inability to establish chronic intracellular
infections. However, before considering why lipid-A alterations
could be important, we will discuss two observations that, at least
on the surface, might seem to be inconsistent with such a model.
First, it has been shown recently that the LPS from an S.
meliloti acpXL mutant (unable to synthesize a particular acyl
carrier protein involved with VLCFA synthesis) (31) lacks
27-OHC28:0 under free-living conditions, yet this mutant is able
to form an effective symbiosis with alfalfa (32) although sub-
stantially less efficiently than a wild-type S. meliloti (32). These
observations have been used to argue that 27-OHC28:0-
containing LPS is beneficial but not essential for the symbiosis.
However, many acyl carrier proteins exist in S. meliloti (33, 34).
Thus, it is possible that one of these is able to substitute for
AcpXL during the nodulation process such that LPS of the S.
meliloti acpXL mutant may contain 27-OHC28:0 modifications
in planta. This seems to be a real possibility because preliminary
studies of the analogous acpXL mutant in the closely related
bacterium Rhizobium leguminosarum have shown that its LPS in
the symbiotic state contains some 27-OHC28:0 (R.W.C., unpub-
lished data), whereas, just as observed with the S. meliloti acpXL
mutant, the LPS in the free-living state lacks 27-OHC28:0 (35).
Thus, for this reason, we do not think that the free-living
properties of the S. meliloti acpXL mutant rule out a critical role
for BacA in symbiosis by it affecting the degree of lipid-A
modification by VLCFAs.
The second issue is raised by our own data because a model
hypothesizing the importance of correct lipid-A structure for
Fig. 2. BacA affects the lipid-A fatty-acid modifications of both S. meliloti and B. abortus. (A) MALDI–TOF MS of S. meliloti wild-type Rm1021 lipid A; major
species [M H] 2039 and [M H] 1939. (B) Same as A, except S. meliloti Rm1021 bacA null mutant; major species [M H] 1516 with lesser amounts of [M
H] 2039 and [M H] 1939. (C) Fatty-acid compositions of S. meliloti wild-type Rm1021 (filled bars) and its bacA null mutant (open bars) lipid A as determined
by GC–MS. (D) MALDI–TOF MS of B. abortus wild-type 2308 lipid A; major species [M H] 2201 and [M H] 2116. (E) Same as D, except B. abortus 2308 bacA
null mutant; major species [M H] 1495, [M H] 1467, [M H] 2202 and [M H] 2116. (F) The fatty-acid composition of B. abortus wild type (filled bars)
and bacA null mutant (open bars) lipid A, as determined by GC–MS. For the MALDI–TOF MS experiments, the proposed composition of the major lipid-A species
identified are shown in Table 1. The remaining ions of lesser intensity, some of which represent lipid A where the 27-OHC28:0 modification has been replaced
with 29-OHC30:0, are due to variation in the chain length of the fatty-acyl substituents.
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chronic intracellular infection has to rationalize why reductions
in the VLCFA modifications of the LPS, ranging from50% for
the S. meliloti and B. abortus bacA null mutants to 20% in the
S. meliloti R389G bacA mutant, could prevent successful chronic
intracellular infection. Because we were unable to detect any
lipid A lacking a VLCFA modification in our LPS preparations
from wild-type S. meliloti and wild-type B. abortus, it is possible
that even a small fraction of LPS lacking a VLCFA modification
may be sufficient to prevent a chronic infection. Furthermore, if
the VLCFA content of LPS increases during S. melilotialfalfa
symbiosis, as it does during R. leguminosarumpea symbiosis
(36), the differences in the VLCFA content of the LPS of the
wild-type strains and respective bacA mutants could be even
more pronounced in the host.
One possible consequence of the reduction of the VLCFA on
lipid A is that it might make the LPS more easily recognized by
the defense systems of the host. Lipid A is a powerful stimulator
of innate immune responses in mammals, and recognition of this
molecule by Toll-like receptors plays a critical role in this process
(37). Toll-like receptors have been identified in plants (38),
where they also contribute to innate immunity. It is well docu-
mented that rhizobial and brucellae lipid-A molecules exhibit
attenuated biological activity and very low endotoxicity com-
pared with enterobacterial lipid-A molecules (39, 40). This low
level of activity of brucellae lipid A is thought to serve as a
mechanism for immune evasion during the initial stages of host
infection. Thus, an interesting model is that the reduced VLCFA
modification of the lipid A in the S. meliloti and B. abortus bacA
mutants renders the LPS more easily detectable by host Toll-like
receptors, thereby inducing a robust innate immune response
and accelerated clearance of the bacA mutants from their hosts.
An alternative or additional consequence of the reduction of the
VLCFA on lipid A is that it could compromise the integrity of
the outer membrane. Unlike shorter-chain LPS fatty acids, the
VLCFAs present in Sinorhizobium and Brucella LPS have the
potential to span the whole outer membrane. Thus, the reduction
in the amount of VLCFAs present in the lipid A of the bacA
mutants could increase their sensitivity to host-derived stresses,
such as exposure to low pH, reactive oxygen intermediates, and
antimicrobial peptides.
What is the molecular mechanism of the BacA protein? As
mentioned earlier, based not only on the sequence similarity
between BacA and the ALDP family of peroxisomal-membrane
proteins but also on the fact that all of these proteins affect
processes involving long-chain fatty acids and VLCFAs, it seems
to be likely that BacA could have a related function. It is known
(22, 23, 41) that members of the ALDP family affect the
transport of activated long-chain fatty acids and VLCFAs out of
the cytoplasm, but their precise mechanistic role is controversial.
They could either act by directly transporting the activated fatty
acid out of the cytoplasm across the peroxisomal membrane or
by facilitating fatty-acid transport out of the cytoplasm by some
other peroxisomal-membrane protein. Similar considerations
apply to the BacA proteins, which could either be involved
directly in the transport of activated fatty acids out of the
cytoplasm across the inner membrane or could facilitate the
transport of fatty acids by another inner-membrane protein. The
simplest model is that BacA is involved directly in the transport
of activated fatty acids. Because the BacA protein is highly
expressed throughout the symbiosis of S. meliloti with alfalfa (9),
this mechanism would permit the bacteria to modify existing
cell-envelope components by fatty-acid addition rather than
having to resynthesize them in the modified form. Because the
B. abortus BacA protein also affects the shorter-chain lipid-A
fatty acids, the B. abortus protein may resemble other members
of the adrenoleukodystrophy family (22) and have a broader
transport specificity compared with the S. meliloti BacA protein.
If this model is correct, then S. meliloti and B. abortus would need
one or more proteins outside of the cytoplasm that could transfer
the activated fatty acids onto the LPS and possibly other
cell-envelope components. Salmonella PagP, an outer-
membrane protein that transfers a fatty acid to existing LPS, is
an example of this general class of protein (42). It is known that
S. meliloti produces a class of nodulation factors that are acylated
with -1-hydroxylated fatty acids ranging from C18 to C26 (43).
However, the occurrence of VLCFAs on other cellular compo-
nents has yet to be determined. Intriguingly, the gene encoding
the S. typhimurium BacA homologue SbmA is only 14 bp away
from yaiW, a gene encoding a putative outer-membrane lipopro-
tein. Although the S. meliloti and B. abortus bacA genes are not
organized in operons and these bacteria lack yaiw, they do
possess many outer-membrane lipoproteins. Thus, the S. meliloti
and B. abortus BacA proteins may also affect acylation of an
outer-membrane lipoprotein.
Why do the bacA mutants still produce some lipid A with a
VLCFA modification? If our model presented above is correct,
then in the free-living state, S. meliloti and B. abortus must have
another mechanism by which lipid A can be modified with a
VLCFA in the absence of BacA. However, the identity of this
system remains to be determined. Although less attractive based
on our sequence comparison data, we cannot rule out alternative
models by which BacA could affect the lipid-A VLCFA content.
In E. coli in which knowledge of the process of LPS assembly and
transport is the most advanced, the lipid A is assembled on the
cytoplasmic face of the inner membrane where MsbA is involved
in a ‘‘f lip-f lop’’ mechanism whereby the rough LPS is moved to
the periplasmic face of the inner membrane (37, 44). Many
MsbA-like proteins are encoded in the S. meliloti genome. Thus,
Fig. 3. Changing S. meliloti BacA residues identical to hALDP affects the amount of lipid A-containing VLCFAs. MALDI–TOF MS of lipid-A molecules from the
S. meliloti bacA null mutant carrying plasmids encoding different mutant BacA proteins (14), pBacA Q193G (A), pBacA D198G or pBacA R284G (B), and pBacA
R389G (C). The lipid-A molecules from the mutants were affected differently, resulting in an increase of [M H] 1515 (which lacks a VLCFA) at the expense of
[MH]1939 and [MH]2039. The MALDI–TOF MS of lipid A from the S. meliloti bacA null mutant carrying either the plasmid pRK404 with no insert (pControl)
or the plasmid pJG51A carrying a wild-type copy of S. meliloti bacA (pBacAWT) were virtually indistinguishable from the MALDI–TOF MS of the bacA null mutant
alone (Fig. 2B) and wild-type S. meliloti (see Fig. 2A), respectively (data not shown). (D) Fatty-acid composition of lipid A from the different mutants, as
determined by GC–MS. For the MALDI–TOF MS experiments, the proposed composition of the major lipid-A species identified are shown in Table 1.
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BacA could potentially influence the activity of one of the
MsbA-like proteins such that, in the absence of BacA, the
‘‘f lipping’’ of rough LPS-containing VLCFAs is less efficient. If
the sole function of BacA were to modify the LPS, then this
MsbA-facilitator model would provide a means by which BacA
could fulfill this function. However, if BacA affects fatty-acid
modification of additional cell-envelope components then the
activated-fatty-acid transport mechanism would be favored.
It is also worth considering that, in addition to the cell-
envelope alteration, the reduction andor absence of BacA
activity in our bacA mutants could also be detrimental to the
bacterial cell within the host. Our group observed previously that
plant cells infected with the S. meliloti bacA null mutant appear
to accumulate aggregates of lipids that are not present during
infection with wild-type S. meliloti (9). When hALDP is defective
in X-linked adrenoleukodystrophy patients, VLCFAs accumu-
late within tissues, and this accumulation ultimately leads to their
misincorporation into the myelin sheath (25, 26). Thus, if BacA
affects the transport of either activated VLCFAs or rough
LPS-containing VLCFA out of the cytoplasm, then in our bacA
mutants in which BacA is either defective or absent, activated
VLCFAs or rough LPS-containing VLCFA could accumulate,
leading to adverse effects on cellular processes. Under free-
living conditions, we observed that the bacA mutants do not have
substantial growth defects. However, if the VLCFA level in-
creases within the host (36), this problem could be exacerbated,
contributing, at least in part, to the death of the bacA mutants
in planta.
In summary, these findings present clear evidence that BacA
affects a fatty-acid modification of at least one component of the
bacterial cell envelope, the LPS. Although the precise role that
this LPS alteration plays in the establishment of chronic infec-
tions is unclear, it is likely to be important. We have noted (14)
that BacA and BacA-related proteins are present in other
bacteria, including the chronic intracellular pathogen Mycobac-
terium tuberculosis. Because Gram-positive bacteria lack LPS,
research into BacA and BacA-related proteins could better
define the role of these proteins in cell-envelope modifications
and the effect that such modifications have on chronic bacteria–
host interactions. In addition, these studies may also yield
important insights regarding the function of the ALDP family of
proteins in eukaryotes.
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